Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ CER review for pediatric testing of musculoskeletal complaints

This article was originally published in The Gray Sheet

Executive Summary

Agency for Healthcare Research and Quality is taking comments through April 19 on five key questions on the comparative effectiveness of antinuclear antibody, rheumatoid factor and citric citrullinated peptide testing to evaluate musculoskeletal complaints in children. AHRQ wants more data on the sensitivity and specificity of tests that are used to help identify juvenile idiopathic arthritis and systemic lupus erythematosus
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel